Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

The cost of providing comprehensive HIV treatment in PEPFAR-supported programs.

Menzies NA, Berruti AA, Berzon R, Filler S, Ferris R, Ellerbrock TV, Blandford JM.

AIDS. 2011 Sep 10;25(14):1753-60. doi: 10.1097/QAD.0b013e3283463eec.

2.

The determinants of HIV treatment costs in resource limited settings.

Menzies NA, Berruti AA, Blandford JM.

PLoS One. 2012;7(11):e48726. doi: 10.1371/journal.pone.0048726. Epub 2012 Nov 7. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/1b6115d9-272e-4623-8ef7-265cd8e5aa28.

3.

Characteristics of HIV care and treatment in PEPFAR-supported sites.

Filler SJ, Berruti AA, Menzies N, Berzon R, Ellerbrock TV, Ferris R, Blandford JM.

J Acquir Immune Defic Syndr. 2011 May 1;57(1):e1-6. doi: 10.1097/QAI.0b013e3182158980.

4.

Costing analysis of national HIV treatment and care program in Vietnam.

Duong AT, Kato M, Bales S, Do NT, Minh Nguyen TT, Thanh Cao TT, Nguyen LT.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):e1-7. doi: 10.1097/QAI.0b013e3182a17d15.

6.

Multi-country analysis of treatment costs for HIV/AIDS (MATCH): facility-level ART unit cost analysis in Ethiopia, Malawi, Rwanda, South Africa and Zambia.

Tagar E, Sundaram M, Condliffe K, Matatiyo B, Chimbwandira F, Chilima B, Mwanamanga R, Moyo C, Chitah BM, Nyemazi JP, Assefa Y, Pillay Y, Mayer S, Shear L, Dain M, Hurley R, Kumar R, McCarthy T, Batra P, Gwinnell D, Diamond S, Over M.

PLoS One. 2014 Nov 12;9(11):e108304. doi: 10.1371/journal.pone.0108304. eCollection 2014.

7.

Annual cost of antiretroviral therapy among three service delivery models in Uganda.

Vu L, Waliggo S, Zieman B, Jani N, Buzaalirwa L, Okoboi S, Okal J, Borse NN, Kalibala S.

J Int AIDS Soc. 2016 Jul 20;19(5 Suppl 4):20840. doi: 10.7448/IAS.19.5.20840. eCollection 2016.

8.

Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study.

Scott CA, Iyer HS, McCoy K, Moyo C, Long L, Larson BA, Rosen S.

BMC Public Health. 2014 Mar 31;14:296. doi: 10.1186/1471-2458-14-296.

9.

Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda.

Jain V, Chang W, Byonanebye DM, Owaraganise A, Twinomuhwezi E, Amanyire G, Black D, Marseille E, Kamya MR, Havlir DV, Kahn JG.

PLoS One. 2015 Dec 3;10(12):e0143433. doi: 10.1371/journal.pone.0143433. eCollection 2015.

10.

Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.

Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y; Cost-Effectiveness of Preventing AIDS Complications (CEPAC) investigators.

AIDS. 2012 Jan 2;26(1):45-56. doi: 10.1097/QAD.0b013e32834dce6e.

11.

Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.

Medina Lara A, Kigozi J, Amurwon J, Muchabaiwa L, Nyanzi Wakaholi B, Mujica Mota RE, Walker AS, Kasirye R, Ssali F, Reid A, Grosskurth H, Babiker AG, Kityo C, Katabira E, Munderi P, Mugyenyi P, Hakim J, Darbyshire J, Gibb DM, Gilks CF; DART Trial Team.

PLoS One. 2012;7(4):e33672. doi: 10.1371/journal.pone.0033672. Epub 2012 Apr 24.

12.

ART treatment costs and retention in care in Kenya: a cohort study in three rural outpatient clinics.

Larson BA, Bii M, Henly-Thomas S, McCoy K, Sawe F, Shaffer D, Rosen S.

J Int AIDS Soc. 2013 Jan 2;16:18026. doi: 10.7448/IAS.16.1.18026.

13.

Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal.

Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, Walensky RP, Messou E, Weinstein MC, Dabis F, Freedberg KA; ART-LINC Collaboration of International Epidemiological Databases to Evaluate AIDS (IeDEA); CEPAC International investigators.

PLoS Med. 2009 Oct;6(10):e1000173. doi: 10.1371/journal.pmed.1000173. Epub 2009 Oct 27.

14.

The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: Findings from a randomised trial evaluating different health care strategies.

Kimaro GD, Mfinanga S, Simms V, Kivuyo S, Bottomley C, Hawkins N, Harrison TS, Jaffar S, Guinness L; REMSTART trial team.

PLoS One. 2017 Feb 24;12(2):e0171917. doi: 10.1371/journal.pone.0171917. eCollection 2017.

15.

Treatment Outcomes and Costs of Providing Antiretroviral Therapy at a Primary Health Clinic versus a Hospital-Based HIV Clinic in South Africa.

Long LC, Rosen SB, Brennan A, Moyo F, Sauls C, Evans D, Modi SL, Sanne I, Fox MP.

PLoS One. 2016 Dec 12;11(12):e0168118. doi: 10.1371/journal.pone.0168118. eCollection 2016.

16.
17.

Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting.

Koenig SP, Schackman BR, Riviere C, Leger P, Charles M, Severe P, Lastimoso C, Colucci N, Pape JW, Fitzgerald DW.

Clin Infect Dis. 2010 Sep 1;51(5):600-8. doi: 10.1086/655762.

19.

Delivering pediatric HIV care in resource-limited settings: cost considerations in an expanded response.

Tolle MA, Phelps BR, Desmond C, Sugandhi N, Omeogu C, Jamieson D, Ahmed S, Reuben E, Muhe L, Kellerman SE; Child Survival Working Group of the Interagency Task Team on the Prevention and Treatment of HIV infection in Pregnant Women, Mothers and Children.

AIDS. 2013 Nov;27 Suppl 2:S179-86. doi: 10.1097/QAD.0000000000000105. Review.

PMID:
24361627
20.

Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia.

Marseille E, Giganti MJ, Mwango A, Chisembele-Taylor A, Mulenga L, Over M, Kahn JG, Stringer JS.

PLoS One. 2012;7(12):e51993. doi: 10.1371/journal.pone.0051993. Epub 2012 Dec 20.

Supplemental Content

Support Center